Company: MDCXW
Filing Date: 2025-09-19
Form Type: DRS
Source: 0001062993-25-015719
Chunk: 176

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-19
Form: DRS
Chunk 176
---
exercised 
  Options Unexercisable 
                 (#)(1) | Option Exercise Price 
                  (C$) | Option          
 Expiration Date |
| Dr. Raza Bokhari   |                 250,000 |                      - |                  1.16 | 10/24/2028      |
|                    |                       - |                 50,000 |                  3.95 | 12/17/2029      |
| James Quinlan      |                 125,000 |                      - |                  1.16 | 10/24/2028      |
|                    |                       - |                 20,000 |                  3.95 | 12/17/2029      |
| Dr. Edward Brennan |                  75,000 |                      - |                  1.16 | 10/24/2028      |
|                    |                       - |                 20,000 |                  3.95 | 12/17/2029      |

<div align='center'>120

CONFIDENTIAL TREATMENT REQUESTED BY MEDICUS PHARMA LTD.

PURSUANT TO 17 C.F.R. SECTION 200.83</div>

(1)All options have vested and are currently exercisable as of the date of this prospectus.

Employment and Consulting Agreements with Executive Officers

We have entered into written employment agreements with James Quinlan, our Chief Financial Officer, Edward Brennan, our Chief Scientific Officer, Faisal Mehmud, our Chief Medical Officer and Andrew Smith, our Chief Operating Officer. Such agreements provide for a base salary, an annual discretionary bonus, notice and payment requirements upon termination without cause or as a result of a change in control, and payments following or in connection with any other termination or resignation. Mr. Quinlan, Mr. Brennan, Mr. Mehmud and Mr. Smith are also subject to non-solicitation and non-competition agreements prohibiting competing with us and soliciting our clients for a period of one year following termination and also prohibiting soliciting our employees, of officers, executives, or agents for a period of one year following termination.

Directors

Compensation of our directors generally consists of annual retainer fees and the Board and committee meeting fees, which are paid on a quarterly basis. There are no special arrangements between us and any director with respect to fees. Our directors are also entitled to participate in our equity incentive plan. Our executive officers who also act as directors do